Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2005

View Archived Issues

Second closing of Cellerant Therapeutics' Series B financing

NAP and ADNF-9 exert neuroprotective effects via PARP-1 activation and polyADP-ribosylation

IFN-alpha-XL shows promise in the management of chronic hepatitis C

First data on the antitumor efficacy of artesunate in metastatic uveal melanoma

Cubist submits Cubicin sNDA filing, requests priority review

Glenmark seeks clearance for phase I trials of DPP-IV inhibitor GRC-8200

International Medical Innovations changes name to PreMD

Revised reporting date for phase III study of Corlux

Corcept closes enrollment in Corlux study in Alzheimer's patients

Low dose oral interferon alpha studied for bone marrow proliferative disorders

ADX-10059 enters phase I studies for anxiety disorders and migraine

VT-111 begins phase II trial for acute coronary syndromes

Actilon begins phase Ib study for chronic HCV

AT-1001 enters phase I testing for celiac disease

Tissue distribution of SVT-40776 indicates a good safety profile

Pentacel BLA accepted for filing

UR-1505 modulates T cell proliferation and cytokine production

New data presented on GSK-3 dual inhibitor that demonstrates bone formation

Lck inhibition prevents acute rejection of heart transplants

Regeneron updates progress of key programs

Exatecan mesilate investigated in metastatic gastric cancer

Approvable letter for iPlex

Positive opinions in Europe for Combigan

Studies reveal temsirolimus activity in different cancers

Stiefel licenses albaconazole from Uriach

Recent patents report novel treatments for obesity

DOV-216303 shows promise in the management of major depression

Phase I data on arsenic trioxide plus dacarbazine in metastatic melanoma

Canvaxin improves survival of patients with high-risk melanoma

New thrombin inhibitors claimed in AstraZeneca patent

BAY-43-9006 shows antitumor activity in metastatic melanoma

Novel agents for diabetes and related complications reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...